Ninety One UK 13F: Cuts Eli Lilly and (LLY) Stake by $261M

Ninety One UK scaled back its investment in Eli Lilly and Company (NYSE: LLY), selling off a notable portion of its holdings during the period. According to a Form 13F filing with the SEC on October 15, 2026, the fund cut its position by 39.5%. Institutional filings like this provide a look back at portfolio moves from the previous quarter and might not reflect the fund's current holdings today.

Inside Ninety One UK's Eli Lilly Trade

The firm cut its stake by 225,437 shares during the quarter, leaving it with 344,968 shares of the drug maker. At the time of the filing, the remaining stake was valued at approximately $399.2 million. The reduction follows a prior holding of 570,405 shares.

Other Institutional Activity in Eli Lilly

Other large institutional investors adjusted their positions in Eli Lilly around the same reporting window. Lilly Endowment, Inc reduced its holdings by 1,516,238 shares, ending with 90,376,978 shares worth about $113.6 billion. Blackrock Inc. grew its holdings by 1,161,629 shares, ending with 67,540,400 shares worth about $84.9 billion. Vanguard Capital Management LLC grew its holdings by 165,427 shares, ending with 53,528,868 shares worth about $67.3 billion. PNC Financial Services Group, Inc. reduced its holdings by 5,133 shares, ending with 51,322,720 shares worth about $64.5 billion. State Street Corporation grew its holdings by 605,376 shares, ending with 36,215,754 shares worth about $45.5 billion.

Eli Lilly and Company Stock Up 3.9%

Eli Lilly shares recently traded around $1,255.32, which is up about 6.5% above its 50-day moving average and about 16.3% above its 200-day moving average. The stock sits about 2.9% below its 52-week high of $1,292.65 and well above its 52-week low of $783.85.

Recent Earnings

Eli Lilly reported trailing-twelve-month revenue of $79.7 billion alongside earnings of $29.79 per share. The company posted a net profit margin of 33.5% and a return on equity of 102.3%, with year-over-year revenue growth coming in at 47.7%. The company's next earnings report is scheduled for October 29, 2026.

Dividend

Eli Lilly pays an annual dividend yielding 0.55%, backed by a dividend payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders executed several stock sales leading up to the filing. Ilya Yuffa, Officer, sold 2,500 shares on June 10, 2026, at an average price of $1,150.77 for a total value of $2,876,925. Anat Hakim, General Counsel, sold 5,000 shares on August 7, 2026, at $1,190.00 per share, totaling $5,950,000. Donald A Zakrowski, Officer, sold 2,000 shares on August 10, 2026, at $1,185.01 per share, worth $2,370,020. Patrik Jonsson, Officer, sold 6,500 shares on August 17, 2026, at $1,175.10 per share, totaling $7,638,150.

Analysts Set New Price Targets

Wall Street firms have continued updating their outlooks on the healthcare stock. On September 22, 2026, TD Cowen reiterated its Buy rating with a $1,250.00 price target. On September 28, 2026, JP Morgan maintained an Overweight rating and raised its target from $1,400.00 to $1,500.00. On October 7, 2026, Morgan Stanley maintained an Overweight rating, lifting its target from $1,419.00 to $1,430.00. On October 8, 2026, Cantor Fitzgerald maintained an Overweight rating while raising its target from $1,410.00 to $1,440.00. On October 12, 2026, RBC Capital reiterated an Outperform rating with a $1,500.00 price target. The stock currently holds a consensus Buy rating from analysts, with a mean price target of $1,328.05.

About Eli Lilly and Company

Headquartered in Indianapolis, Indiana, Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products globally. The healthcare bellwether focuses on treatments across multiple therapeutic categories, drawing close attention from institutional portfolio managers as its product pipeline evolves.

Bottom Line

Ninety One UK's cut is part of a broader picture of institutional rebalancing in Eli Lilly shares. Investors will look toward the upcoming earnings release on October 29, 2026, for further insight into the company's financial momentum. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.